Could erythropoietin reduce the ovarian damage of cisplatin in female rats?

Basit Öğe Kaydı
dc.contributor.authorSayan, Cemile Dayangan
dc.contributor.authorTulmac, Ozlem Banu
dc.contributor.authorKaraca, Gokhan
dc.contributor.authorOzkan, Zehra Sema
dc.contributor.authorYalcin, Selim
dc.contributor.authorDevrim, Tuba
dc.contributor.authorBadem, Nermin Dindar
dc.date.accessioned2020-06-25T18:30:08Z
dc.date.available2020-06-25T18:30:08Z
dc.date.issued2018
dc.departmentKırıkkale Üniversitesi
dc.descriptionOzkan, Zehra Sema/0000-0001-9185-3663
dc.description.abstractThe aim of this study is to investigate whether erythropoietin (EPO) can reduce the ovarian damage of cisplatin or not. Thirty, female, Wistar-Albino rats were used in the study. Control group (N=10): Intraperitoneal saline infusion, Cisplatin group (N=10): Intraperitoneal 7mg/kg cisplatin, Cisplatin+EPO group (N=10): Intraperitoneal 7mg/kg cisplatin and subcutaneous 200IU/kg/day EPO. Serum AMH concentrations were measured by enzyme-linked immunosorbent assay kit of AMH. Follicular counts were evaluated according to mean diameter of the follicles. Ovarian damage; including follicular cell degeneration, vascular congestion, hemorrhage, and inflammation was scored histologically using a graduated scale. Posttreatment AMH levels of cisplatin group were significantly lower than control and cisplatin+EPO groups. In cisplatin group, there was a significant decrement in posttreatment AMH level compared to pretreatment AMH level. The total damage score of cisplatin group was significantly higher than scores of control and cisplatin+EPO groups. The mean primordial follicle counts of control and cisplatin+EPO groups were significantly higher than that of cisplatin group (p=.007 and p=.003). The results of this study revealed that EPO administration to cisplatin chemotherapy could ameliorate the ovarian damage. Erythropoietin administration to chemotherapeutic agents might suggest to protect ovarian failure and infertility.en_US
dc.description.sponsorshipKirikkale University Scientific Research Commission [2015/06]en_US
dc.description.sponsorshipThis research was funded by Kirikkale University Scientific Research Commission (project number: 2015/06). The authors are grateful to Kirikkale University, for their valuable support.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1080/09513590.2017.1395836
dc.identifier.endpage313en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue4en_US
dc.identifier.pmid29084473
dc.identifier.scopus2-s2.0-85032666685
dc.identifier.scopusqualityQ2
dc.identifier.startpage309en_US
dc.identifier.urihttps://doi.org/10.1080/09513590.2017.1395836
dc.identifier.urihttps://hdl.handle.net/20.500.12587/7567
dc.identifier.volume34en_US
dc.identifier.wosWOS:000428813900013
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofGynecological Endocrinology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCisplatinen_US
dc.subjecterythropoietinen_US
dc.subjectovaryen_US
dc.subjectAMHen_US
dc.titleCould erythropoietin reduce the ovarian damage of cisplatin in female rats?en_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Could erythropoietin reduce the ovarian damage of cisplatin in female rats.pdf
Boyut:
1.87 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu